FXIa-6f is a high affinity, orally bioavailable macrocyclic FXIa inhibitor with antithrombotic activity in preclinical species

EMD 495235是一种有效的口服活性凝血因子Xa (factor Xa)抑制剂，IC50为5.5 nM，Ki为6.8 nM，并显示抗凝血活性。

NCGC00351170 是一种抗血小板药物，能够干扰钙-整合素结合蛋白1 (CIB1) 与 αIIbβ3 的相互作用，并抑制凝血素诱导的人类血小板聚集。

Edoxaban impurity 6 is an impurity of Edoxaban. Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with Kis of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and can be used for stroke prevention[1][2]. [1]. Furugohri T, et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost. 2008 Sep;6(9):1542-9.[2]. Mendell J, Lee F, Chen S, The Effects of the Antiplatelet Agents, Aspirin and Naproxen, on Pharmacokinetics and Pharmacodynamics of the Anticoagulant Edoxaban, a Direct Factor Xa Inhibitor. J Cardiovasc Pharmacol. 2013 Apr 23.

Anivamersen是一种RNA核酸适配体，可逆转凝血因子factor Ixa抑制剂pegnivacogin的抗凝作用。Pegnivacogin（凝血因子IXa的RNA适体抑制剂）和Anivamersen（互补序列反转寡核苷酸）构成了一种新型抗凝系统[REG1]。

TVB-3664 是一种具有口服具有活力的、选择性的、可逆的、具有高生物利用度的脂肪酸合酶抑制剂，其对人和老鼠棕榈酸酯合成的IC50分别为 18 nM 和 12 nM。可显著抑制微管蛋白棕榈酰化和 mRNA 表达。